N6-methyladenosine (m6A) RNA modification in chronic myeloid leukemia: unveiling a novel therapeutic target
Open Access
- 31 July 2024
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 81 (1) , 1-13
Abstract
N6-methyladenosine (m6A), the most prevalent internal mRNA modification, plays a critical role in physiological processes by regulating gene expression through modulation of mRNA metabolism at multiple stages. In recent years, m6A has garnered significant attention for a deeper understanding of the initiation, progression, and drug resistance of various cancers, including hematological malignancies. Dysregulation of m6A has been implicated in both cancer promotion and suppression. m6A methylation is a complex regulatory process involving methyltransferases (writers), demethylases (erasers), and proteins that recognize specific m6A modifications (readers). This intricate interplay presents challenges for precisely modulating m6A levels, either globally or at specific sites. This review specifically focuses on the role of m6A in chronic myeloid leukemia (CML), a blood cancer characterized by the BCR-ABL1 fusion. We emphasize its impact on leukemia cell survival and drug resistance mechanisms. Notably, inhibitors targeting m6A regulators show promise in preclinical models, suggesting a potential therapeutic avenue for CML. Integrating our understanding of m6A biology with current treatment strategies may lead to more effective therapies, especially for patients with advanced-stage or resistant CML.Keywords
This publication has 62 references indexed in Scilit:
- XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancerCancer Letters, 2024
- Enhancing sensitivity of triple‐negative breast cancer to DNA‐damaging therapy through chemical inhibition of the m6A methyltransferase METTL3Cancer Communications, 2023
- Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein responseCellular and Molecular Life Sciences, 2023
- YBX1 regulates the survival of chronic myeloid leukemia stem cells by modulating m6A-mediated YWHAZ stabilityCellular Oncology, 2022
- The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemiaCancer Cell, 2022
- N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiationCancer Cell, 2021
- A Unified Model for the Function of YTHDF Proteins in Regulating m6A-Modified mRNACell, 2020
- Response and Resistance to BCR-ABL1-Targeted TherapiesCancer Cell, 2020
- Deciphering the “m6A Code” via Antibody-Independent Quantitative ProfilingCell, 2019
- Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop CodonsCell, 2012